ATE158414T1 - Neue gabaa-rezeptorsubtypen und verfahren zum screening von arzneimittelverbindungen unter verwendung von gabaa-rezeptorsubtypen bindende imidazochinoxaline und pyrrolopyrimidine - Google Patents

Neue gabaa-rezeptorsubtypen und verfahren zum screening von arzneimittelverbindungen unter verwendung von gabaa-rezeptorsubtypen bindende imidazochinoxaline und pyrrolopyrimidine

Info

Publication number
ATE158414T1
ATE158414T1 AT93910819T AT93910819T ATE158414T1 AT E158414 T1 ATE158414 T1 AT E158414T1 AT 93910819 T AT93910819 T AT 93910819T AT 93910819 T AT93910819 T AT 93910819T AT E158414 T1 ATE158414 T1 AT E158414T1
Authority
AT
Austria
Prior art keywords
receptor subtypes
gabaa receptor
imidazochinoxalines
pyrrolopyrimidines
new
Prior art date
Application number
AT93910819T
Other languages
English (en)
Inventor
Kenneth Shaw
Alan Hutchison
Andrew Thurkauf
John Tallman
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Application granted granted Critical
Publication of ATE158414T1 publication Critical patent/ATE158414T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT93910819T 1992-04-30 1993-04-30 Neue gabaa-rezeptorsubtypen und verfahren zum screening von arzneimittelverbindungen unter verwendung von gabaa-rezeptorsubtypen bindende imidazochinoxaline und pyrrolopyrimidine ATE158414T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/876,050 US5597920A (en) 1992-04-30 1992-04-30 Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes

Publications (1)

Publication Number Publication Date
ATE158414T1 true ATE158414T1 (de) 1997-10-15

Family

ID=25366890

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910819T ATE158414T1 (de) 1992-04-30 1993-04-30 Neue gabaa-rezeptorsubtypen und verfahren zum screening von arzneimittelverbindungen unter verwendung von gabaa-rezeptorsubtypen bindende imidazochinoxaline und pyrrolopyrimidine

Country Status (12)

Country Link
US (2) US5597920A (de)
EP (1) EP0639275B1 (de)
JP (1) JPH08500333A (de)
KR (1) KR950702032A (de)
AT (1) ATE158414T1 (de)
AU (1) AU691470B2 (de)
CA (1) CA2134227A1 (de)
DE (1) DE69314024T2 (de)
DK (1) DK0639275T3 (de)
ES (1) ES2110090T3 (de)
GR (1) GR3025698T3 (de)
WO (1) WO1993022681A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
JP3868502B2 (ja) * 1996-10-25 2007-01-17 ニューロサーチ・アクティーゼルスカブ 抗不安作用を有する化合物の同定方法
US6737242B1 (en) 1999-05-07 2004-05-18 Neurogen Corporation Methods for screening GABA-modulatory compounds for specified pharmacological activities
CA2371219A1 (en) * 1999-05-07 2000-11-16 Neurogen Corporation Methods for screening gaba-modulatory compounds for specified pharmacological activities
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ZA200301701B (en) * 2000-09-15 2004-03-01 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI1318997T1 (sl) * 2000-09-15 2006-12-31 Vertex Pharma Pirazolne spojine, uporabne kot inhibitorji protein-kinaze
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
MX2008005814A (es) 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
NZ582879A (en) 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
MX2011002312A (es) 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7900456L (sv) * 1978-05-31 1979-07-20 Ferrosan As Bensodiazeptinkoncentrationsbestemning
IL90315A0 (en) * 1988-06-01 1989-12-15 Ferrosan As Imidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
EP0738717A1 (de) * 1990-10-09 1996-10-23 Neurogen Corporation Substituierte Pyrimidine als Intermediate für die Herstellung von Cycloalkyl- und Azacycloalkylpyrrolopyrimidine
US5130430A (en) * 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
AU4117493A (en) * 1992-04-08 1994-11-21 Neurogen Corporation Certain aryl fused pyrrolopyrimidines; a new class of gaba brain receptor ligands

Also Published As

Publication number Publication date
AU691470B2 (en) 1998-05-21
US5688654A (en) 1997-11-18
GR3025698T3 (en) 1998-03-31
DK0639275T3 (da) 1998-04-14
US5597920A (en) 1997-01-28
KR950702032A (ko) 1995-05-17
DE69314024D1 (de) 1997-10-23
WO1993022681A1 (en) 1993-11-11
DE69314024T2 (de) 1998-04-16
EP0639275A1 (de) 1995-02-22
ES2110090T3 (es) 1998-02-01
AU4117793A (en) 1993-11-29
EP0639275B1 (de) 1997-09-17
CA2134227A1 (en) 1993-11-11
JPH08500333A (ja) 1996-01-16

Similar Documents

Publication Publication Date Title
ATE158414T1 (de) Neue gabaa-rezeptorsubtypen und verfahren zum screening von arzneimittelverbindungen unter verwendung von gabaa-rezeptorsubtypen bindende imidazochinoxaline und pyrrolopyrimidine
DE69717308D1 (de) Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit
ATE247667T1 (de) Gdnf-rezeptor und dessen verwendung
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE314479T1 (de) Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden
DE69627193T2 (de) Dimer-selektive rxr modulatoren und verfahren zu ihrer verwendung
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
DE69020918D1 (de) Decahydroisoquinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
ATE171472T1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
DE69414398D1 (de) Heterocyclische neurokinin-antagonisten
DE69712745D1 (de) Pyrrolopyrimidinen und verfahren zu deren herstellung
DE69633624D1 (de) Lösliche lymphotoxin-beta -rezeptoren, antikörper gegen den lymphotoxinrezeptor und ligand-antikörper als therapeutische reagenzien in der behandlung von immunkrankheiten
ATE193553T1 (de) Domänen von extrazellulären bereichen von menschlichen blutplättchen abstammenden wachstumsfaktor rezeptor-polypeptiden
ATE238800T1 (de) Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
DK0553319T3 (da) Fremgangsmåde til adskillelse af en plastblanding bestående af mindst tre komponenter under anvendelse af elektrostatiske teknikker
DE58903736D1 (de) Verfahren zur behandlung von biomassen, z.b. klaerschlaemmen, guelle, usw.
DK0473671T3 (da) Anvendelse af sigma-receptorligander til fremstilling af et anxiolytisk middel
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE3770901D1 (de) Verfahren und katalysatorsystem zur trimerisierung von acetylen und acetylenverbindungen.
EA199700242A1 (ru) Индазолкарбоксамиды, способ их получения, фармкомпозиция и способ ингибирования 5-нтрецептора
EP0656791A4 (de) Therapeutische zusammensetzungen und verfahren unter verwendung von pqq.
AT375367B (de) Verfahren zur herstellung von als histamin h2-rezeptor-antagonisten wirkenden nitroverbindungen
TR199902192T2 (xx) Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri
DE3673381D1 (de) Verfahren zum fraktionieren von steinkohlenteerpech und verwendung der dabei erhaeltlichen fraktionen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee